Our dedicated API and PFI manufacturing sites, Bonthapally and Jeedimetla continue to be strengthened through an increase in capacities and Regulatory accreditations. Through the acquisition of Auctus Pharmaceuticals (now Unit IV) in 2013, we took over a multi-product API manufacturing facility at Vizag and an intermediary manufacturing facility at Bonthapally both of which will augment our vision towards integration.

At Unit V, our Multi API facility, we manufacture small to medium volume APIs that are forward integrated into our finished dosages and sold to third party consumers.

Our Gagillapur unit is one of the largest single unit manufacturing site for PFIs and Finished Dosages which we are further adding to by increasing technology based capacities. In an effort towards forward integration, we set up a formulation R&D and manufacturing facility in Virginia, USA to develop and commercialize oral solid dosages in the US. This facility also gives us the ammunition to address any changes in the policies directed towards “Make in America.”